Iopofosine I-131 Under Further Investigation in CLOVER WaM Trial in Waldenström Macroglobulinemia
June 23rd 2022
Sikander Ailawadhi, MD, discusses early efficacy observed with iopofosine I-131, the rationale of investigating the agent in the CLOVER WaM trial in patients with Waldenström macroglobulinemia, and how the radiotherapeutic could affect the treatment paradigm.